Sort
10,766 grants matching “checkpoint inhibitor”
Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122
$673,408Antonio M Omuro · Yale University · R01 · FY2023 · CA
Autoimmunity in Cardiopulmonary Toxicities from Radiotherapy and Immunotherapy
$673,394Bo Lu · Thomas Jefferson University · R01 · FY2022 · CA
Antifungal Immunity and the Mechanism of Fungal Programmed Cell Death
$672,949Tobias M Hohl · Sloan-Kettering Inst Can Research · R01 · FY2019 · AI
A physical sciences approach to investigate the role of exosomes in metastatic progression
$672,673Ravi Radhakrishnan · University Of Pennsylvania · U01 · FY2025 · CA
Cancer immunotherapy
$672,569Eytan Ruppin · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Genetically engineered mouse model to improve therapy of NUT carcinoma
$672,468Christopher A French · Brigham And Women'S Hospital · R01 · FY2023 · CA
Ultra-sensitive mass spectrometry-based immunopeptidomics using digital microfluidics.
$672,371Etienne Caron · Yale University · R61 · FY2025 · CA
Mechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal Malignancies
$672,300Pavlos Msaouel · University Of Tx Md Anderson Can Ctr · R37 · FY2024 · CA
Mechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal Malignancies
$672,300Pavlos Msaouel · University Of Tx Md Anderson Can Ctr · R37 · FY2025 · CA
Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor
$672,297David John Tweardy · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Advancing immunotherapy through cross species studies of immune cell responses and immune checkpoint inhibitor effects in dogs and humans with invasive urinary bladder cancer
$672,254Deborah W Knapp · Purdue University · U01 · FY2025 · CA
Novel Target, New Therapy: Anti- Renalase Antibody for Tumors Resistant to PD-1Inhibitors
$672,231Barry A Berkowitz · Bessor Pharma, Llc · R44 · FY2022 · CA
Data Processing, Analysis and Modeling Unit
$672,104Jeremy Goecks · Oregon Health & Science University · U2C · FY2020 · CA
Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor
$671,795David John Tweardy · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma
$671,746Reeder McNeil Robinson · Leukogene Therapeutics, Inc. · R42 · FY2022 · CA
Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor
$671,730David John Tweardy · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Role of AMPK in melanoma brain metastasis
$671,615Bin Zheng · Cedars-Sinai Medical Center · R01 · FY2025 · CA
Optimizing Dual-Targeted and Dual-Armored CAR T Cells for Small Cell LungCancer
$671,440Renier Joseph Brentjens · Roswell Park Cancer Institute Corp · U01 · FY2024 · CA
(8) Genetics of Immune Related Adverse Events and Response to Immunotherapy
$671,059Elad Ziv · University Of California, San Francisco · R01 · FY2021 · CA
Elucidating T Cell Ferroptosis in Renal Medullary Carcinoma: 3D Genome Architecture Rewiring and Therapeutic Alleviation
$671,046Liuqing Yang · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Modulation of cancer induced immune suppression via inhibition of SCD1
$670,441Karen E Hayes · Modulation Therapeutics, Inc. · R44 · FY2024 · CA
Dissecting the role of B lineage cells in mediating response of resectable lung cancer to neoadjuvant immune-based therapy
$670,358Tina Cascone · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Dissecting the role of B lineage cells in mediating response of resectable lung cancer to neoadjuvant immune-based therapy
$670,358Tina Cascone · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Project 1: Transgenic TCR-mediated tumor therapy
$669,971Philip D Greenberg · University Of Washington · P01 · FY2020 · CA
Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics
$669,970Beth A. Reboussin · Wake Forest University Health Sciences · U01 · FY2023 · CA